4.2 Article

Safety data from randomized controlled trials: applying models for recurrent events

Journal

PHARMACEUTICAL STATISTICS
Volume 15, Issue 4, Pages 315-323

Publisher

WILEY
DOI: 10.1002/pst.1757

Keywords

randomized controlled trials; safety data; adverse events; recurrent events; survival analysis

Funding

  1. Pfizer Deutschland GmbH

Ask authors/readers for more resources

Simple descriptive listings and inference statistics based on 2x2 tables are still the most common way of summarizing and reporting adverse events data from randomized controlled trials, although these methods do not account for differences in observation times between treatment groups. Using standard methods from survival analysis such as the Cox model or Kaplan-Meier estimates would overcome this problem but limit the analysis to the first safety-related event of each subject. As an alternative, we discuss two models for recurrent events datathe Andersen-Gill and Prentice-Williams-Peterson modelregarding their applicability to safety data from randomized controlled trials. We argue that these models can be used to estimate two different quantities: a direct treatment effect on the risk of an event (Prentice-Williams-Peterson) and a total treatment effect as sum of the direct effect and the treatment's indirect effect via the event history (Anderson-Gill). Using simulated data, we illustrate the difference between these treatment effects and analyze the performance of both models in different scenarios. Because both models are limited to the analysis of cause-specific hazards if competing risks are present, we suggest to incorporate estimates of the mean frequency of events in the analysis to additionally allow the comparison of treatment effects on absolute event probabilities. We demonstrate the application of both models and the mean frequency function to safety endpoints with an illustrative analysis of data from a randomized phase-III study. Copyright (c) 2016 John Wiley & Sons, Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Meeting Abstract Economics

PATIENT PROFILE OF NEW USERS OF NOVEL ORAL ANTICOAGULANTS IN NON-VALVULAR ATRIAL FIBRILLATION (NVAF): REAL-WORLD EVIDENCE FROM PRIMARY CARE DATA IN GERMANY

C. Lefevre, M. Johnson, A. Maguire, S. Collings, S. Kloss, D. Evans

VALUE IN HEALTH (2015)

Meeting Abstract Cardiac & Cardiovascular Systems

COMPARISON OF TREATMENT PERSISTENCE IN THE REAL-WORLD USE OF NOVEL ORAL ANTICOAGULANTS AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

Cinira Lefevre, Michelle Johnson, Shuk-Li Collings, David Evans, Sebastian Kloss, Essra Ridha, Andrew Maguire

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)

Meeting Abstract Cardiac & Cardiovascular Systems

CHANGES OVER TIME IN TREATMENT PERSISTENCE OF ORAL ANTICOAGULANTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

Cinira Lefevre, Michelle Johnson, Shuk-Li Collings, David Evans, Sebastian Kloss, Essra Ridha, Andrew Maguire

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)

Article Medicine, General & Internal

Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care

Michelle E. Johnson, Cinira Lefevre, Shuk-Li Collings, David Evans, Sebastian Kloss, Essra Ridha, Andrew Maguire

BMJ OPEN (2016)

Review Pharmacology & Pharmacy

The positive impacts of Real-World Data on the challenges facing the evolution of biopharma

John Wise, Angeli Moeller, David Christie, Dipak Kalra, Elia Brodsky, Evelina Georgieva, Greg Jones, Ian Smith, Lars Greiffenberg, Marie McCarthy, Michael Arendt, Olivier Luttringern, Sebastian Kloss, Steve Arlington

DRUG DISCOVERY TODAY (2018)

Article Pharmacology & Pharmacy

High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications

E. Garbe, S. Kloss, M. Suling, I. Pigeot, S. Schneeweiss

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)

Article Public, Environmental & Occupational Health

Linkage of mother-baby pairs in the German Pharmacoepidemiological Research Database

Edeltraut Garbe, Marc Suling, Sebastian Kloss, Christina Lindemann, Ulrike Schmid

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)

Meeting Abstract Economics

EVALUATION OF THE LENGTH OF HOSPITAL STAY FOR PATIENTS WITH ATRIAL FIBRILLATION

F. Volz, S. Kloss, F. Muschaweck, M. Wilke, F. Leverkus

VALUE IN HEALTH (2013)

Meeting Abstract Economics

AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) LEVEL PREDICTION IN POPULATION-BASED ADMINISTRATIVE DATABASES IN THE ABSENCE OF RECORDED LABORATORY VALUES

F. Kleinjung, T. Vaitsiakhovich, A. Gedranovich, V Hedranovich, S. Kloss, Y. Balabanova, B. Schaefer, D. Markouski

VALUE IN HEALTH (2018)

Article Public, Environmental & Occupational Health

High-dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reporting

Jeremy A. Rassen, Patrick Blin, Sebastian Kloss, Romain S. Neugebauer, Robert W. Platt, Anton Pottegard, Sebastian Schneeweiss, Sengwee Toh

Summary: This article provides an overview of the high-dimensional propensity score (hdPS) method and recommendations for its planning, implementation, and reporting in longitudinal healthcare databases. A checklist is provided as a decision tool to aid researchers and decision-makers in understanding and interpreting studies using hdPS techniques.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

No Data Available